Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.65
+0.02 (0.36%)
May 14, 2025, 10:17 AM - Market open
Abeona Therapeutics Employees
Abeona Therapeutics had 136 employees as of December 31, 2024. The number of employees increased by 52 or 61.90% compared to the previous year.
Employees
136
Change (1Y)
52
Growth (1Y)
61.90%
Revenue / Employee
n/a
Profits / Employee
-$468,632
Market Cap
274.22M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ABEO News
- 2 hours ago - UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder - GlobeNewsWire
- 2 hours ago - Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder - GlobeNewsWire
- 2 hours ago - Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder - GlobeNewsWire
- 2 days ago - Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewsWire
- 6 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
- 15 days ago - US FDA approves Abeona's skin disorder therapy - Reuters
- 15 days ago - U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire